Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Trials in Progress: The Randomized, Double-Blind, Placebo-Controlled Phase 1b CROSSWALK-a and Phase 2a CROSSWALK-c Trials - Crovalimab for the Treatment and Prevention of Vaso-Occlusive Episodes in Sickle Cell Disease

Marco Aurelio Salvino, Bulent Antmen, Frederick Chite Asirwa, Satheesh Chonat, Lucia De Franceschi, Perla Eleftheriou, Adlette Inati, Johnny Mahlangu, Erfan Nur, Salvador Payán-Pernía, Asad Charania, Diana Gradinaru, Allison Hsia, Yves Luder, Thomas Perretti, Sasha Srekovic, Pablo Bartolucci

Blood (2023) 142 (Supplement 1): 1158.

https://doi.org/10.1182/blood-2023-179858

Published: 2023

Journal Articles

Treatment with IMR-687, a Highly Selective PDE9 Inhibitor, Increases HbF and Reduces VOCs in Adults with Sickle Cell Disease in a Long-Term, Phase 2a, Open-Label Extension Study

Biree Andemariam, Timothy Mant, Perla Eleftheriou, Sanne Lugthart, Lanetta Bronté-Hall, Filipa Barroso, Gershwin Blyden, James Mason, Constance M Barysauskas, Joseph Yen, Karen Tang, Rahul Ballal, Kenneth Attie

Blood (2021) 138 (Supplement 1): 2046.

https://doi.org/10.1182/blood-2021-149536

Published: 2021

Journal Articles

Benefits and Safety of Long-Term Use of IMR-687 As Monotherapy or in Combination with a Stable Dose of Hydroxyurea (HU) in 2 Adult Sickle Cell Patients

Lanetta Bronte-Hall, MD MPH, MSPH, Biree Andemariam, MD, Blyden Gershwin, MD, Sanne Lugthart, MD PhD, Timothy Mant, MB, FFPM, FRCP, Jo Howard, MBBChir, MRCP, FRCPath, Henry Fok, MBBS, PhD, Perla Eleftheriou, FRCPath, MRCP, Robert Ward Hagar, MD, James Mason, DO, Rahul Ballal, PhD, Joelle Lufkin, MPH, Eleanor Lisbon, MD MPH

Blood (2020) 136 (Supplement 1): 29–30.

https://doi.org/10.1182/blood-2020-140540

Published: 2020

Journal Articles

Evaluating the Volumetric Liver Fat Fraction in Patients Referred for Investigation of Hyperferritinemia

Aoife Dervin, MBBS, BSc, MRCP, Perla Eleftheriou, FRCPath, MRCP, Deepak Suri, MBBS FRCP, Sara Trompeter, MBChB BSc MRCPCH FRCPath MSc, Maciej W Garbowski, MD PhD, Tim St. Pierre, John B. Porter, MA MDFRCP FRCPath, Emma Drasar, MBBS MRCP FRCPath PhD

Blood (2019) 134 (Supplement_1): 3539.

https://doi.org/10.1182/blood-2019-128122

Published: 2019

Journal Articles

Pregnancy Outcomes in Patients with Sickle Cell Syndromes Managed Antenatally with Exchange Transfusions: A Single Centre Analysis

Evangelia Vlachodimtropoulou Koumoutsea, MBBS, Hutachok Nuntouchaporn, BSc, Perla Eleftheriou, FRCPath, MRCP, Patrick O'Brien, John Porter, MA MDFRCP FRCPath

Blood (2018) 132 (Supplement 1): 3666.

https://doi.org/10.1182/blood-2018-99-113619

Published: 2018

Journal Articles

Real-World Experience of Switching from Deferasirox Dispersible to Film-Coated Tablets: Impact on Adherence to Chelation Therapy, Iron Overload and Renal Function

Simon Cheesman, Raakhee Shah, MPharm, Sara Trompeter, MD, Perla Eleftheriou, FRCPath, MRCP, Bernadette Hylton, RN, Maciej W Garbowski, MDPhD, John Porter, MA MDFRCP FRCPath

Blood (2018) 132 (Supplement 1): 1062.

https://doi.org/10.1182/blood-2018-99-119030

Published: 2018

Journal Articles

Use of Eculizumab for the Treatment of Hyperhaemolysis in Pregnancy in Sickle Cell Disease: A Case Report

Laura Chebet Kirui, MRCP, FRCPath, Marie Scully, MD MRCP, FRCPath, Norma Mcqueen, Bsc, John Porter, MA MDFRCP FRCPath, Perla Eleftheriou, FRCPath, MRCP

Blood (2018) 132 (Supplement 1): 4922.

https://doi.org/10.1182/blood-2018-99-118396

Published: 2018

Journal Articles

Impact of Compliance, Ferritin and LIC on Long-Term Trends in Myocardial T2* with Deferasirox

Maciej Garbowski, Perla Eleftheriou, Dudley Pennell, Mark Tanner, John B Porter

Blood (2008) 112 (11): 116.

https://doi.org/10.1182/blood.V112.11.116.116

Published: 2008

Journal Articles

MRI Evidence of Cardiac Iron Accumulation in Myelodysplasia and Unusual Anaemias.

Julie Glanville, Perla Eleftheriou, John Porter

Blood (2006) 108 (11): 1553.

https://doi.org/10.1182/blood.V108.11.1553.1553

Published: 2006

Journal Articles

Improved Myocardial T2* in Transfusion Dependent Anemias Receiving ICL670 (Deferasirox).

John B. Porter, MD, Mark A. Tanner, MRCP, Dudley J. Pennell, MD, Perla Eleftheriou, MD

Blood (2005) 106 (11): 3600.

https://doi.org/10.1182/blood.V106.11.3600.3600

Published: 2005

NARROW

Trials in Progress: The Randomized, Double-Blind, Placebo-Controlled Phase 1b CROSSWALK-a and Phase 2a CROSSWALK-c Trials - Crovalimab for the Treatment and Prevention of Vaso-Occlusive Episodes in Sickle Cell Disease

Treatment with IMR-687, a Highly Selective PDE9 Inhibitor, Increases HbF and Reduces VOCs in Adults with Sickle Cell Disease in a Long-Term, Phase 2a, Open-Label Extension Study

Benefits and Safety of Long-Term Use of IMR-687 As Monotherapy or in Combination with a Stable Dose of Hydroxyurea (HU) in 2 Adult Sickle Cell Patients

Evaluating the Volumetric Liver Fat Fraction in Patients Referred for Investigation of Hyperferritinemia

Pregnancy Outcomes in Patients with Sickle Cell Syndromes Managed Antenatally with Exchange Transfusions: A Single Centre Analysis

Real-World Experience of Switching from Deferasirox Dispersible to Film-Coated Tablets: Impact on Adherence to Chelation Therapy, Iron Overload and Renal Function

Use of Eculizumab for the Treatment of Hyperhaemolysis in Pregnancy in Sickle Cell Disease: A Case Report

Impact of Compliance, Ferritin and LIC on Long-Term Trends in Myocardial T2* with Deferasirox

MRI Evidence of Cardiac Iron Accumulation in Myelodysplasia and Unusual Anaemias.

Improved Myocardial T2* in Transfusion Dependent Anemias Receiving ICL670 (Deferasirox).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only